利洁时拟售美赞臣大中华业务 据报贝恩资本、凯雷、伊利、红杉中国等竞逐
外电3月下旬曾报道,英国消费品巨擘利洁时(Reckitt Benckiser),计划出售美赞臣婴儿配方奶粉大中华区业务。据《彭博通讯社》引述消息称,私募基金包括贝恩资本、凯雷集团及KKR均参与首轮入标;另伊利股份(600887.SH)及新希望乳业(002946.SZ)亦参与初步竞购。消息称,利洁时冀以高达20亿美元(155.32亿港元)出售有关业务。据悉,红杉中国亦参与竞购。
利洁时在2月公布相关资产出售策略评估消息,当时称大中华业务占集团总收入的6%。集团去年总收入为140亿英镑。利洁时在2017年收购美赞臣,涉及交易金额166亿美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.